For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
2
views
22
references
 Top references
cited by
51
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      2,392
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer : A Randomized Clinical Trial

      Author(s): 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 1 , 17 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , 18 , Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group
      Publication date (Electronic):
      Journal: JAMA Oncology
      Publisher: American Medical Association (AMA)

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

          Thierry Conroy, Pascal Hammel, Mohamed Hebbar … (2018)
          Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.
          Article 0 comments Cited 786 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

            J Ferlay, M Colombet, I Soerjomataram … (2018)
            Europe contains 9% of the world population but has a 25% share of the global cancer burden. Up-to-date cancer statistics in Europe are key to cancer planning. Cancer incidence and mortality estimates for 25 major cancers are presented for the 40 countries in the four United Nations-defined areas of Europe and for Europe and the European Union (EU-28) for 2018.
            Article 0 comments Cited 761 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

              John Neoptolemos, Daniel H Palmer, Paula Ghaneh … (2017)
              The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcitabine and capecitabine than with gemcitabine alone in advanced or metastatic pancreatic cancer. We aimed to determine the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer.
              Article 0 comments Cited 634 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: JAMA Oncology
                Abbreviated Title: JAMA Oncol
                Publisher: American Medical Association (AMA)
                ISSN (Print): 2374-2437
                Publication date (Electronic): September 01 2022
                Affiliations
                [1 ]Medical Oncology department, Institut de cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France and Université de Lorraine, APEMAC, équipe MICS, Nancy, France
                [2 ]Biometry Department, ICM Regional Cancer Institute of Montpellier, Montpellier, France and Montpellier University, Montpellier, France
                [3 ]Hepatogastroenterology department, University Hospital, Nancy, France
                [4 ]Medical Oncology Department, University hospital, Lille, France and University of Lille, Lille, France
                [5 ]Medical Oncology Department, ICANS, Strasbourg, France
                [6 ]Surgery department, Princess Margaret Hospital, Toronto, Ontario, Canada
                [7 ]Medical Oncology department, Institut Paoli-Calmettes, Marseille, France
                [8 ]Department of Oncology, Queen’s University, Canada
                [9 ]Medical oncology department, Centre Antoine-Lacassagne, Nice, France
                [10 ]Hepatogastroenterology department, Hôpital Jean-Mermoz, Lyon, France
                [11 ]Hepatogastroenterology department, Hôpital Trousseau, Tours, France and INSERM UMR 6239, Tours University, Tours, France
                [12 ]Medical oncology department, Centre Hospitalier Universitaire de Saint-Eloi, Montpellier, France
                [13 ]Hepatogastroenterology department, Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France
                [14 ]Oncology department, ICM Regional Cancer Institute of Montpellier, Montpellier, France and Montpellier University, Montpellier, France
                [15 ]Digestive oncology department, Centre Hospitalier Universitaire Robert Debré, Reims, France
                [16 ]R&D, Unicancer, Paris, France
                [17 ]Digestive and Medical Oncology department, Hôpital Paul Brousse and University Paris-Saclay, Villejuif, France
                [18 ]for the Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group
                Article
                DOI: 10.1001/jamaoncol.2022.3829
                PubMed ID: 36048453
                SO-VID: 8a48cfea-3337-4863-8151-5d257e9eaf06
                Copyright © © 2022
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content2,392

                See all similar

                Cited by51

                See all cited by

                Most referenced authors739

                See all reference authors